INTERNATIONAL CHAMBER OF COMMERCE
INTERNATIONAL COURT OF ARBITRATION
Case No. 27914/MHM
KESTREL DYNAMICS GmbH Industriestraße 88, 70565 Stuttgart, Germany (German Trade Register No. HRB 745621, Amtsgericht Stuttgart)
Claimant
v.
WHITMORE AEROSPACE LLC 4200 Wilson Boulevard, Suite 1100, Arlington, VA 22203 (Delaware LLC; EIN 54-3298710)
Respondent
RESPONDENT'S STATEMENT OF DEFENSE AND COUNTERCLAIM
Date Filed: June 30, 2023
Submitted by:
Calderwood & Harkness LLP 600 Lexington Avenue New York, NY 10022
Counsel for Respondent:
Theodore Langston, Partner Vivienne St. Claire, Partner Simone Laroche, Senior Associate Jeffrey Park, Associate
Responding to: Claimant's Statement of Claim dated April 28, 2023
Place of Arbitration: New York, New York
Language of Arbitration: English
Arbitration Rules: ICC Rules of Arbitration (2021 edition)
Tribunal:
• Prof. Dame Eleanor Fitzwilliam, Presiding Arbitrator
• Dr. Hans-Ulrich Perren, Co-Arbitrator (Claimant's nominee)
• Hon. Robert A. Castillo, Co-Arbitrator (Respondent's nominee)
I. INTRODUCTION
1. Respondent Whitmore Aerospace LLC ("WAL" or "Respondent") respectfully submits this Statement of Defense and Counterclaim to the Tribunal in response to the Statement of Claim filed by Kestrel Dynamics GmbH ("Kestrel" or "Claimant") on April 28, 2023, in accordance with the procedural calendar established by the Tribunal in Procedural Order No. 1 dated February 14, 2023.
2. WAL is a privately held Delaware limited liability company headquartered at 4200 Wilson Boulevard, Suite 1100, Arlington, Virginia 22203. WAL is engaged in the business of aerospace and defense manufacturing, specializing in propulsion systems and structural airframe components for both military and commercial aviation platforms. For the fiscal year ending December 31, 2022, WAL reported annual revenue of approximately $1.87 billion and employed approximately 6,400 individuals across its facilities in the United States.
3. Kestrel is a Gesellschaft mit beschränkter Haftung organized and existing under the laws of the Federal Republic of Germany, registered in the German Trade Register under No. HRB 745621 at the Amtsgericht Stuttgart, with its principal offices at Industriestraße 88, 70565 Stuttgart, Germany. Kestrel specializes in precision-machined titanium and nickel-alloy turbine housings and high-temperature exhaust assemblies for the aerospace and industrial turbine industries. For the fiscal year ending December 31, 2022, Kestrel reported annual revenue of approximately €312 million and employed approximately 1,800 individuals.
4. Kestrel commenced this arbitration by filing its Request for Arbitration with the International Chamber of Commerce on November 7, 2022, alleging that WAL committed material breach of the Master Supply Agreement for Titanium Alloy Turbine Housings dated June 15, 2018 (the "MSA," internally referenced as WAL-KDG-MSA-2018-0615). In its Statement of Claim, Kestrel seeks damages in the aggregate amount of approximately €47.3 million, comprising claims for lost profits over the remaining term of the MSA and two optional renewal periods, unreimbursed rework costs, and reputational damages.
5. WAL denies Kestrel's allegations in their entirety. The record in this matter will demonstrate that WAL's termination of the MSA on October 3, 2022 was proper and fully justified under Section 14.2(b) of the MSA, which grants either party the right to terminate upon the occurrence of a "Persistent Quality Failure" as defined in Section 8.4. Far from committing material breach, WAL acted in strict accordance with its contractual rights after Kestrel repeatedly delivered non-conforming products that failed to meet the expressly agreed-upon porosity specifications set forth in WAL-SPEC-TH-401, Appendix C, Table 3, and thereafter failed to cure within the contractually prescribed timeframes. WAL did not fabricate or exaggerate quality deficiencies. WAL did not apply unpublished or stricter specifications. WAL did not terminate the MSA as a pretext for engaging a cheaper domestic supplier — indeed, the replacement supplier's unit price was substantially higher than Kestrel's.
6. In addition to defending against Kestrel's unfounded claims, WAL asserts a counterclaim against Kestrel in the amount of €5.17 million. This sum represents the direct cost premium that WAL incurred in procuring replacement titanium alloy turbine housings from Valkyr Precision Components Inc. ("Valkyr") following Kestrel's Persistent Quality Failure. WAL was compelled to source 1,680 replacement units from Valkyr at a significant per-unit premium in order to mitigate the disruption to its downstream manufacturing operations caused by Kestrel's repeated delivery of non-conforming products. These cover damages are direct damages recoverable under New York law, and they are not barred by the consequential damages waiver contained in Section 8.7 of the MSA.
7. This Statement of Defense and Counterclaim is organized as follows: Section II sets forth the relevant procedural history; Section III describes the key provisions of the MSA; Section IV presents WAL's statement of the material facts; Section V responds to each of Kestrel's principal allegations; Section VI addresses and rebuts each category of Kestrel's claimed damages; Section VII sets forth WAL's counterclaim; Section VIII presents WAL's legal arguments; Sections IX and X address the expert and witness evidence WAL intends to submit; Section XI states the relief sought; and Section XII provides a list of exhibits and documentary evidence.
II. PROCEDURAL HISTORY
A. Execution and Amendments to the MSA
8. On June 15, 2018, WAL, as Buyer, and Kestrel, as Seller, executed the Master Supply Agreement for Titanium Alloy Turbine Housings (internally referenced as WAL-KDG-MSA-2018-0615) (the "MSA"). The MSA is the governing agreement between the parties that establishes the terms and conditions for Kestrel's manufacture and delivery of Ti-6Al-4V ELI titanium alloy turbine housings to WAL. A true and correct copy of the MSA is submitted as Exhibit R-1.
9. The MSA was entered into for an initial term of five years, commencing on June 15, 2018 and expiring on June 14, 2023, with two optional one-year renewal periods exercisable solely at WAL's discretion (Section 3.1 of the MSA). The MSA was the product of extensive arm's-length negotiations between two sophisticated commercial entities, each represented by experienced counsel and each possessing substantial expertise in the aerospace manufacturing industry.
10. The MSA was amended on two occasions during its term:
(a) Amendment No. 1, dated February 10, 2020. Amendment No. 1 expanded the scope of the MSA to include Products manufactured to WAL engineering specification WAL-SPEC-TH-410, a high-temperature variant of the turbine housing designed for next-generation propulsion applications. Amendment No. 1 also increased the maximum annual volume from 3,600 to 4,000 units per contract year to accommodate anticipated increases in WAL's production requirements. A true and correct copy of Amendment No. 1 is submitted as Exhibit R-2.
(b) Amendment No. 2, dated September 3, 2021. Amendment No. 2 was entered into by mutual agreement in recognition of the ongoing disruptions to global supply chains and logistics networks caused by the COVID-19 pandemic. Amendment No. 2 extended the contractual cure period under Section 8.4 from 30 calendar days to 45 calendar days, providing Kestrel with additional time to cure any non-conformance identified through WAL's incoming inspection process. Amendment No. 2 also added a force majeure carve-out specifically addressing pandemic-related delays. A true and correct copy of Amendment No. 2 is submitted as Exhibit R-3.
11. It bears emphasis that Amendment No. 2 was a concession made by WAL in Kestrel's favor, extending the cure period by 50% (from 30 to 45 days). Despite this accommodation, Kestrel was still unable to cure a substantial number of rejected lots within the extended timeframe, as discussed in detail below.
B. The Dispute and Termination
12. Beginning in March 2022, WAL's incoming quality-control inspections began identifying elevated porosity levels in Products delivered by Kestrel. Between March 7, 2022 (the delivery date of Lot KDG-2022-0307) and September 19, 2022 (the delivery date of Lot KDG-2022-0919), WAL rejected a total of 14 lots of Products, comprising 1,680 individual units, for non-conformance with the contractual porosity specifications set forth in WAL-SPEC-TH-401, Appendix C, Table 3.
13. For each rejected lot, WAL provided Kestrel with timely written notice of rejection specifying the nature of the non-conformance and affording Kestrel the opportunity to cure within the 45-calendar-day period mandated by Section 8.4, as amended by Amendment No. 2. Of the 14 rejected lots, Kestrel successfully cured 7 by delivering replacement or reworked units within the cure period. However, for the remaining 7 lots, Kestrel failed to cure within the 45-day window. These 7 uncured rejections all occurred within a single rolling 12-month period.
14. Under Section 8.4 of the MSA, three or more uncured rejections within any rolling 12-month period constitute a "Persistent Quality Failure." With 7 uncured rejections — more than double the contractual threshold — the occurrence of a Persistent Quality Failure was beyond dispute. Accordingly, on October 3, 2022, WAL issued its Notice of Termination for Cause under Section 14.2(b) of the MSA, identifying the 7 uncured rejections, the specific lot numbers, and the applicable contractual provisions. The termination was both procedurally and substantively proper.
C. Commencement of Arbitration
15. The procedural history of this arbitration is as follows:
(a) On November 7, 2022, Kestrel filed its Request for Arbitration with the International Chamber of Commerce, International Court of Arbitration, pursuant to the arbitration clause contained in Section 22.3 of the MSA.
(b) On December 12, 2022, WAL filed its Answer to the Request for Arbitration and Counterclaim with the ICC, denying Kestrel's allegations and asserting WAL's counterclaim for replacement-component costs.
(c) On January 20, 2023, the Tribunal was constituted. Prof. Dame Eleanor Fitzwilliam was appointed as Presiding Arbitrator. Dr. Hans-Ulrich Perren was confirmed as the Co-Arbitrator nominated by Claimant. The Honorable Robert A. Castillo was confirmed as the Co-Arbitrator nominated by Respondent.
(d) On February 14, 2023, the Tribunal conducted a preliminary procedural conference with the parties. Following the conference, the Tribunal issued Procedural Order No. 1, which established, inter alia, the procedural calendar for the arbitration, including the schedule for written submissions, document production, expert and witness evidence, and the hearing.
(e) On March 17, 2023, the Tribunal issued Procedural Order No. 2, establishing the schedule and procedures for document production. The parties thereafter exchanged document requests and produced responsive documents in accordance with Procedural Order No. 2.
(f) On April 28, 2023, Kestrel filed its Statement of Claim, to which this submission responds.
16. This Statement of Defense and Counterclaim is filed in accordance with the procedural calendar established in Procedural Order No. 1. WAL reserves all rights to submit further evidence and argument in accordance with the Tribunal's orders and the applicable ICC Rules of Arbitration.
III. THE MASTER SUPPLY AGREEMENT
17. This Section summarizes the key provisions of the MSA relevant to the issues in dispute. The full text of the MSA is submitted as Exhibit R-1, and the full texts of Amendment No. 1 and Amendment No. 2 are submitted as Exhibits R-2 and R-3, respectively.
A. Scope of the MSA
18. Under the MSA, Kestrel agreed to manufacture and deliver Ti-6Al-4V ELI (Extra Low Interstitial) titanium alloy turbine housings (the "Products") in accordance with WAL's engineering specifications WAL-SPEC-TH-401 through WAL-SPEC-TH-409 (Section 2.1). Following the execution of Amendment No. 1, the scope of the MSA was expanded to include Products manufactured to WAL engineering specification WAL-SPEC-TH-410, a high-temperature variant designed for advanced propulsion applications. Copies of WAL-SPEC-TH-401 (including Appendix C, Table 3) and WAL-SPEC-TH-402 through WAL-SPEC-TH-410 are submitted as Exhibits R-4 and R-5, respectively.
19. The Products are mission-critical components used in WAL's propulsion systems and structural airframe assemblies. The quality and dimensional integrity of the Products are essential to the safety and performance of the end-use platforms. For this reason, the MSA contained rigorous quality specifications and testing protocols, which Kestrel expressly agreed to satisfy.
20. Delivery of the Products was to be made DDP (Delivered Duty Paid) to WAL's manufacturing facility located at 8500 Coppermine Road, Manassas, Virginia 20110, in accordance with Incoterms 2020 (Section 6.1). Under the DDP delivery term, Kestrel bore all costs and risks associated with transporting the Products to WAL's facility, including customs duties, import clearances, and insurance.
B. Volume and Pricing
21. The MSA established both minimum and maximum annual volume commitments:
(a) Minimum Annual Volume Commitment: WAL committed to order a minimum of 2,400 units of Products per contract year (Section 4.1). This minimum volume commitment reflected WAL's baseline production requirements and provided Kestrel with a guaranteed minimum revenue floor.
(b) Maximum Annual Volume: The maximum annual volume was initially set at 3,600 units per contract year. Following the execution of Amendment No. 1, the maximum annual volume was increased to 4,000 units to accommodate WAL's anticipated growth in production requirements.
22. Pricing for the Products was established on a per-unit basis, with a 2.5% annual escalator compounded annually in accordance with Section 5.2. The per-unit prices for each contract year were as follows:
23. At the minimum annual volume of 2,400 units, the aggregate contract value over the five-year initial term was approximately €61.2 million. The pricing structure reflected the arm's-length negotiation between the parties and accounted for anticipated increases in raw material costs, labor costs, and other inputs.
C. Quality Requirements
24. The MSA imposed stringent quality requirements on Kestrel, reflecting the safety-critical nature of the Products and the regulatory environment in which WAL operates. The principal quality requirements include the following:
(a) AS9100 Rev D Certification. Kestrel was required to maintain AS9100 Rev D certification — the internationally recognized quality management system standard for the aviation, space, and defense industries — at all times during the term of the MSA (Section 7.1). Kestrel's AS9100 Rev D certification and related audit records are submitted as Exhibit R-16.
(b) WAL Incoming Inspection. Each lot of Products delivered by Kestrel was subject to incoming inspection by WAL in accordance with WAL-QCP-100, WAL's standard incoming quality-control procedure (Section 7.3). WAL-QCP-100 establishes the testing methodologies, sampling protocols, and acceptance/rejection criteria applicable to incoming shipments. A copy of WAL-QCP-100 is submitted as Exhibit R-6.
(c) Acceptance or Rejection Period. WAL was required to accept or reject each lot within 15 business days of delivery (Section 7.4). If WAL failed to accept or reject a lot within this period, the lot would be deemed accepted, subject to latent defects discoverable only upon subsequent testing or use.
(d) Porosity Specification. The critical specification at issue in this arbitration is the porosity tolerance for the Products. WAL-SPEC-TH-401, Appendix C, Table 3 expressly establishes a maximum porosity tolerance of ≤0.25% for all Products manufactured under the MSA. This specification was negotiated, agreed upon, and understood by both parties at the time of MSA execution and was not modified at any time during the term of the MSA.
25. The porosity specification of ≤0.25% reflects an industry-standard requirement for Ti-6Al-4V ELI titanium alloy components used in safety-critical aerospace applications. Porosity — the presence of voids or gas pockets within the metal matrix — directly affects the structural integrity, fatigue life, and fracture resistance of titanium alloy components. Elevated porosity levels can lead to premature fatigue failure, potentially with catastrophic consequences in propulsion and airframe applications. The ≤0.25% threshold was established by WAL's engineering team based on extensive testing, materials science analysis, and regulatory requirements, and it was incorporated into the WAL engineering specifications that formed an integral part of the MSA.
D. Rejection, Cure, and Persistent Quality Failure (§ 8.4)
26. Section 8.4 of the MSA establishes the framework for rejection of non-conforming lots and the cure process:
(a) If WAL rejects a lot for non-conformance with the applicable specifications, WAL shall provide written notice to Kestrel specifying the nature of the non-conformance.
(b) Upon receipt of a rejection notice, Kestrel shall have 45 calendar days (as amended by Amendment No. 2; originally 30 calendar days) to cure the non-conformance by delivering replacement Products or reworked Products that conform to the applicable specifications.
(c) If Kestrel fails to cure within the 45-calendar-day period, the rejection shall be deemed "uncured."
(d) Three or more uncured rejections within any rolling 12-month period shall constitute a "Persistent Quality Failure."
27. The Persistent Quality Failure provision serves a critical function in the contractual framework. It provides a clear, objective, and measurable threshold beyond which a pattern of quality non-conformance is deemed sufficiently serious to warrant termination. The threshold of three uncured rejections in a rolling 12-month period was negotiated between the parties as a reasonable standard that would protect WAL against chronic quality problems while providing Kestrel with adequate opportunity to address and correct isolated quality excursions.
E. Exclusive Remedy and Consequential Damages Waiver (§ 8.7)
28. Section 8.7 of the MSA establishes the exclusive remedies available to WAL in the event of quality failures and contains a mutual waiver of consequential damages. Specifically:
(a) WAL's remedies for quality failures are limited to (i) replacement of non-conforming Products at Kestrel's cost, (ii) credit against future orders, or (iii) termination of the MSA upon the occurrence of a Persistent Quality Failure in accordance with Section 14.2(b).
(b) Both parties expressly waive any and all claims for consequential, incidental, special, punitive, or indirect damages arising out of or in connection with the MSA, including but not limited to lost profits, lost revenue, loss of use, and loss of business opportunities.
29. The consequential damages waiver was a material term of the MSA, negotiated at arm's length between two sophisticated commercial parties with extensive experience in aerospace contracting. As will be demonstrated below, this waiver bars the majority of Kestrel's claimed damages.
F. Termination for Cause (§ 14.2)
30. Section 14.2 of the MSA provides two grounds for termination for cause:
(a) Section 14.2(a) — Material Breach. Either party may terminate the MSA upon a material breach by the other party that remains uncured for 60 calendar days following written notice specifying the breach.
(b) Section 14.2(b) — Persistent Quality Failure. Either party may terminate the MSA upon the occurrence of a Persistent Quality Failure, as defined in Section 8.4. No additional cure period is required for termination under Section 14.2(b); the cure periods under Section 8.4 constitute the cure opportunity, and the occurrence of a Persistent Quality Failure (three or more uncured rejections in a rolling 12-month period) triggers the termination right immediately.
31. WAL terminated the MSA under Section 14.2(b) on October 3, 2022, following the occurrence of a Persistent Quality Failure comprising seven uncured rejections within a single rolling 12-month period. WAL did not terminate under Section 14.2(a), and the analysis of whether a "material breach" occurred under general principles of contract law is accordingly irrelevant to the propriety of WAL's termination — the termination was exercised pursuant to an express, self-contained contractual mechanism with its own defined trigger.
G. Governing Law and Dispute Resolution
32. The MSA is governed by the laws of the State of New York, without regard to its conflict-of-laws principles (Section 22.1). All disputes arising out of or in connection with the MSA are to be resolved by arbitration administered by the International Chamber of Commerce under the ICC Rules of Arbitration (2021 edition), before a tribunal of three arbitrators, with the seat of arbitration in New York, New York (Section 22.3). The language of the arbitration is English.
IV. STATEMENT OF FACTS
A. Performance Under the MSA (2018–2021)
33. From the date of execution of the MSA on June 15, 2018 through early 2022, the contractual relationship between WAL and Kestrel proceeded without significant quality disputes. During this period, Kestrel manufactured and delivered Products to WAL in substantial conformity with the MSA's specifications, and WAL accepted the vast majority of deliveries following its standard incoming inspection process under WAL-QCP-100. The parties enjoyed a productive commercial relationship, and WAL's supply chain team worked collaboratively with Kestrel's commercial and quality-assurance personnel to manage production schedules, forecasts, and occasional minor quality excursions that were promptly addressed and cured.
34. The key WAL personnel involved in the day-to-day management of the supply relationship with Kestrel were Gerald Huang, Vice President of Global Supply Chain Operations, who was responsible for procurement, vendor management, and commercial communications with Kestrel; and Dr. Ingrid Vollmer, Senior Vice President of Engineering and Manufacturing, who oversaw the quality-control inspection process and the application of WAL's engineering specifications to incoming shipments.
35. The principal Kestrel personnel with whom WAL interacted were Friedrich Brenner, Managing Director (Geschäftsführer) of Kestrel, who held ultimate responsibility for Kestrel's business operations; Luisa Erdmann, Commercial Director, who served as the primary commercial contact and liaison with WAL; and Dr. Stefan Voss, Head of Quality Assurance, who was responsible for Kestrel's internal quality-control processes and for coordinating with WAL on quality matters.
36. During the first three-and-a-half years of the MSA's term, there were occasional isolated quality excursions — as is normal in any high-volume precision-manufacturing relationship — but these were addressed through the contractual cure mechanisms without escalation. Kestrel's track record during this period demonstrates that the ≤0.25% porosity specification was achievable and was in fact consistently achieved by Kestrel for an extended period. The quality failures that emerged in March 2022 were therefore not attributable to any deficiency in the specification itself, but rather to a breakdown in Kestrel's manufacturing process controls.
B. Quality Failures Commencing March 2022
37. Beginning in March 2022, WAL's incoming inspection under WAL-QCP-100 began detecting elevated porosity levels in Products delivered by Kestrel. The first rejected lot was Lot KDG-2022-0307, delivered to WAL's Manassas facility on or about March 7, 2022. WAL's testing of Lot KDG-2022-0307 revealed porosity levels at multiple sample points within the lot that exceeded the contractual maximum of ≤0.25% as established in WAL-SPEC-TH-401, Appendix C, Table 3.
38. The rejection of Lot KDG-2022-0307 was followed by a cascading series of additional quality failures over the ensuing six months. Between March 7, 2022 and September 19, 2022, WAL rejected a total of 14 lots comprising 1,680 individual units for non-conformance with the contractual porosity specifications. The final rejected lot in this series was Lot KDG-2022-0919, delivered on or about September 19, 2022. The lot numbers, delivery dates, and porosity measurements for each of the 14 rejected lots are set forth in detail in the lot rejection notices submitted as Exhibit R-7.
39. To confirm the accuracy and reliability of its incoming inspection results, WAL engaged Arclight Materials Science Inc. ("Arclight"), a nationally recognized independent metallurgical testing laboratory headquartered at 7900 Westpark Drive, Suite 200, McLean, Virginia 22102, to conduct independent testing of samples from the rejected lots. The independent testing was conducted under the supervision of Dr. Raymond Chow, Principal Engineer at Arclight, who applied industry-standard test methods for porosity determination in titanium alloy components. Dr. Chow's testing confirmed porosity levels in the rejected lots ranging from 0.19% to 0.38%, with the majority of samples exceeding the ≤0.25% contractual limit. The Arclight testing data for the rejected lots is submitted as Exhibit R-9.
40. It is important to address the range of porosity measurements at this stage, as WAL anticipates that Kestrel will attempt to exploit the fact that some measurements within the rejected lots fell below 0.25%. As explained in further detail in Section V.B below, the porosity measurements represent results from multiple sample points within each lot. Under WAL-QCP-100, a lot is accepted or rejected on a lot-wide basis. If any sample point within a lot exceeds the ≤0.25% threshold, the entire lot is rejected, even if other sample points within the same lot measure below 0.25%. The range of 0.19% to 0.38% reflects the full distribution of measurements across all sample points within all 14 rejected lots — it does not reflect WAL's acceptance/rejection threshold.
C. WAL's Rejection and Cure Process
41. For each of the 14 rejected lots, WAL followed the contractual rejection and cure process precisely as specified in Section 8.4 of the MSA, as amended by Amendment No. 2. Specifically:
(a) Upon completing its incoming inspection and determining that a lot failed to meet the contractual specifications, WAL issued timely written notice of rejection to Kestrel. Each rejection notice identified the specific lot number, the nature of the non-conformance (porosity exceedance), the measured porosity levels, and the applicable specification (WAL-SPEC-TH-401, Appendix C, Table 3, maximum porosity ≤0.25%). The 14 rejection notices are collectively submitted as Exhibit R-7.
(b) Each rejection notice expressly advised Kestrel of its right to cure within 45 calendar days by delivering replacement Products or reworked Products conforming to the applicable specifications.
(c) WAL monitored the cure periods and tracked Kestrel's responses to each rejection notice. Kestrel's cure responses and related records are submitted as Exhibit R-8.
42. Of the 14 rejected lots, Kestrel successfully cured 7. For these 7 lots, Kestrel delivered replacement or reworked units within the 45-calendar-day cure period that conformed to the ≤0.25% porosity specification upon re-inspection by WAL. WAL accepted these cured lots and integrated the replacement units into its production processes.
43. For the remaining 7 lots, Kestrel failed to cure within the 45-calendar-day period. In some instances, Kestrel attempted cure but delivered replacement or reworked units that also failed inspection. In other instances, Kestrel failed to deliver any cure within the prescribed timeframe. In all 7 cases, the cure period expired without a successful cure, and the rejections were accordingly deemed "uncured" under Section 8.4.
44. The 7 uncured rejections occurred between March and September 2022 — a span of approximately seven months, well within a single rolling 12-month period. The contractual threshold for a Persistent Quality Failure under Section 8.4 is three uncured rejections within any rolling 12-month period. With 7 uncured rejections, WAL exceeded the threshold by more than double, leaving no reasonable dispute that a Persistent Quality Failure had occurred.
D. Kestrel's Awareness and Inadequate Response
45. Throughout the March–September 2022 period, WAL maintained regular correspondence with Kestrel regarding the quality failures and the status of cure efforts. Correspondence between Gerald Huang (WAL) and Luisa Erdmann (Kestrel) during this period reflects WAL's repeated notifications of the porosity non-conformances, requests for root-cause analysis, and expressions of concern regarding the escalating pattern of quality failures. This correspondence is submitted as Exhibit R-10.
46. Similarly, technical-level correspondence between Dr. Ingrid Vollmer (WAL) and Dr. Stefan Voss (Kestrel) during the same period reflects WAL's detailed communication of the inspection results, including specific porosity measurements, sample point locations, and applicable specification requirements. Dr. Vollmer repeatedly urged Dr. Voss to identify and address the root cause of the porosity exceedances and offered WAL's technical cooperation to assist in the diagnostic process. This correspondence is submitted as Exhibit R-11.
47. Kestrel acknowledged receipt of the rejection notices and the associated correspondence. However, Kestrel failed to identify or remediate the root cause of the persistent porosity exceedances. Kestrel's responses, while timely in form, were substantively inadequate. Kestrel did not provide WAL with any credible root-cause analysis during the relevant period, did not demonstrate that it had implemented effective corrective actions, and did not present evidence that the underlying manufacturing process issue had been resolved.
48. Of particular significance, Kestrel's own internal quality-assurance records — obtained by WAL through the document production process conducted pursuant to Procedural Order No. 2 — demonstrate that Kestrel's internal testing identified porosity levels above 0.25% in several of the rejected lots prior to shipment to WAL. These records, submitted as Exhibit R-15, reveal that Dr. Stefan Voss's quality-assurance team detected elevated porosity levels in pre-shipment testing but nevertheless authorized the release and shipment of the non-conforming lots to WAL. This evidence is directly relevant to the question of Kestrel's culpability and undermines any suggestion that the porosity exceedances were attributable to factors outside Kestrel's control or that WAL's inspection results were inaccurate.
E. WAL's Notice of Termination for Cause (October 3, 2022)
49. On October 3, 2022, following the expiration of the cure period for the seventh uncured lot rejection, WAL issued its Notice of Termination for Cause to Kestrel in accordance with Section 14.2(b) of the MSA. The notice was delivered in writing to Kestrel at its registered address and to its Commercial Director, Luisa Erdmann, by both overnight courier and electronic mail. A true and correct copy of the Notice of Termination is submitted as Exhibit R-12.
50. The Notice of Termination for Cause identified the following:
(a) The occurrence of a Persistent Quality Failure under Section 8.4, consisting of seven uncured rejections within a single rolling 12-month period, far exceeding the contractual threshold of three;
(b) The specific lot numbers of the seven uncured rejected lots;
(c) The nature of the non-conformance for each lot (porosity exceedance above the ≤0.25% contractual limit);
(d) The applicable MSA provisions (Sections 8.4 and 14.2(b)); and
(e) The effective date of termination.
51. The termination was procedurally proper in all respects. WAL complied with the notice requirements of the MSA, identified the specific contractual basis for termination, and provided Kestrel with full transparency regarding the grounds for its decision. The termination was also substantively proper: the Persistent Quality Failure had unambiguously occurred, the contractual conditions for termination under Section 14.2(b) were satisfied, and WAL was entitled — indeed, was compelled by sound business judgment and its obligations to its own downstream customers and regulators — to exercise its termination right.
F. WAL's Engagement of Valkyr Precision Components Inc.
52. Following Kestrel's repeated quality failures and WAL's termination of the MSA, WAL was faced with an urgent need to secure an alternative source of specification-compliant Ti-6Al-4V ELI titanium alloy turbine housings. WAL's downstream manufacturing operations depend on a continuous supply of these safety-critical components, and any extended disruption in supply would have jeopardized WAL's ability to meet its own contractual obligations to its military and commercial aviation customers.
53. After conducting a competitive solicitation among qualified alternative suppliers, WAL engaged Valkyr Precision Components Inc. ("Valkyr"), a U.S.-based precision aerospace components manufacturer headquartered at 4401 East Irvington Road, Tucson, Arizona 85714, as its replacement supplier for titanium alloy turbine housings. Valkyr is an AS9100 Rev D-certified manufacturer with established capabilities in Ti-6Al-4V ELI titanium alloy machining and demonstrated experience in producing turbine housings to aerospace-grade specifications. The Valkyr supply agreement and associated invoices are submitted as Exhibit R-13.
54. Three aspects of WAL's engagement of Valkyr warrant particular emphasis in the context of this arbitration:
(a) Timing. The decision to engage Valkyr was made after, not before, Kestrel's Persistent Quality Failure and WAL's lawful termination of the MSA. WAL did not pre-arrange a replacement supplier as part of a premeditated scheme to terminate the MSA. To the contrary, WAL engaged Valkyr as an emergency mitigation measure necessitated by Kestrel's own quality failures.
(b) Cost. Valkyr's unit price was €8,432.92 per unit, representing a substantial premium over Kestrel's CY4 price of €5,222.92 per unit. Even accounting for Valkyr's introductory discount of 4.2%, Valkyr's adjusted unit price remained significantly higher than Kestrel's price. This fact decisively refutes Kestrel's allegation that WAL terminated the MSA as a pretext for replacing Kestrel with a lower-cost domestic supplier. WAL's engagement of Valkyr was an economically costly necessity, not a cost-saving measure.
(c) Reasonableness. WAL sourced from Valkyr at the most competitive price available among qualified alternative suppliers capable of manufacturing Ti-6Al-4V ELI titanium alloy turbine housings to WAL's specifications. WAL's decision to engage Valkyr was commercially reasonable and constituted a good-faith effort to mitigate the disruption caused by Kestrel's quality failures.
55. WAL sourced 1,680 replacement units from Valkyr at the premium price to replace the non-conforming Products that Kestrel had failed to deliver in specification-compliant form. The per-unit cost premium and the total cost of replacement form the basis of WAL's counterclaim, as set forth in Section VII below.
V. RESPONSE TO CLAIMANT'S ALLEGATIONS
56. In this Section, WAL responds to each of the principal allegations set forth in Kestrel's Statement of Claim. WAL denies Kestrel's allegations in their entirety and demonstrates that each allegation is unsupported by the contractual language, the factual record, and applicable law.
A. WAL Did Not Commit Material Breach of the MSA
57. In its Statement of Claim, Kestrel alleges that WAL committed material breach of the MSA by (i) wrongfully rejecting 14 lots totaling 1,680 units between March and September 2022, and (ii) issuing the Notice of Termination for Cause on October 3, 2022, allegedly based on fabricated or exaggerated quality deficiencies. Kestrel asserts that WAL's actions were taken in bad faith and were designed to manufacture a pretext for terminating the MSA and replacing Kestrel with a domestic supplier.
58. WAL categorically denies these allegations. The rejections were based on objective, verifiable porosity exceedances identified through WAL's standard incoming inspection process under WAL-QCP-100 and confirmed by independent metallurgical testing conducted by Arclight Materials Science Inc. under the supervision of Dr. Raymond Chow. The porosity levels measured in the rejected lots ranged from 0.19% to 0.38% across all sample points, with the determinative measurements — those that triggered lot-level rejection — exceeding the ≤0.25% contractual limit set forth in WAL-SPEC-TH-401, Appendix C, Table 3.
59. WAL followed the contractual rejection and cure procedures precisely as specified in Section 8.4 of the MSA. For each rejected lot, WAL issued timely written notice of rejection, identified the specific non-conformance, and provided Kestrel with the full 45-calendar-day cure period as extended by Amendment No. 2. WAL accepted all lots that were successfully cured within the cure period. WAL's conduct was entirely consistent with the rights and obligations established by the MSA, and it does not constitute a breach — material or otherwise — of any contractual provision.
60. The allegation that WAL fabricated or exaggerated quality deficiencies is not only false but is directly contradicted by the documentary evidence, including: (i) WAL's contemporaneous inspection records under WAL-QCP-100; (ii) the independent Arclight testing data confirming the porosity exceedances; and (iii) Kestrel's own internal quality-assurance records, which demonstrate that Kestrel's pre-shipment testing detected elevated porosity levels in several of the rejected lots before they were shipped to WAL. If anything, the evidence establishes that it was Kestrel — not WAL — that acted improperly, by shipping Products that its own quality-assurance team had identified as potentially non-conforming.
B. WAL Did Not Apply Unpublished or Stricter Specifications
61. A central pillar of Kestrel's Statement of Claim is the contention that WAL's incoming inspections applied an unpublished porosity tolerance of ≤0.15%, which is stricter than the contractual specification of ≤0.25%. According to Kestrel, WAL unilaterally tightened the acceptance criteria without notice to Kestrel, resulting in the wrongful rejection of lots that would have been accepted under the contractual standard.
62. This allegation is false, and the evidence demonstrates its falsity conclusively.
63. The contractual porosity limit of ≤0.25% is expressly stated in WAL-SPEC-TH-401, Appendix C, Table 3 — a document that was negotiated, agreed upon, and incorporated into the MSA at the time of its execution. Kestrel received, acknowledged, and agreed to this specification. There is no ambiguity in the language of the specification, and there is no credible basis for Kestrel's suggestion that WAL applied a different standard.
64. WAL's inspection protocol under WAL-QCP-100 measures porosity against the published specification of ≤0.25%. WAL's inspection records, which will be submitted through the testimony of Dr. Ingrid Vollmer and the expert report of Dr. Raymond Chow, demonstrate a clear and consistent pattern: lots were accepted when the porosity measurements at all sample points within the lot were at or below 0.25%, and lots were rejected only when porosity exceeded 0.25% at one or more sample points.
65. Kestrel appears to base its allegation on the observation that some porosity measurements within the rejected lots were as low as 0.19%. Kestrel reasons that if WAL were applying the contractual ≤0.25% threshold, lots with measurements as low as 0.19% should not have been rejected. This reasoning reflects a fundamental misunderstanding — whether genuine or feigned — of WAL's lot-level inspection methodology.
66. Under WAL-QCP-100, porosity is measured at multiple sample points within each lot. A lot is not evaluated on the basis of a single measurement or an average of measurements; rather, a lot is rejected if any sample point within the lot exceeds the ≤0.25% threshold. In the lots where individual measurements as low as 0.19% were recorded, other sample points within the same lot yielded measurements exceeding 0.25%, resulting in lot-level rejection. The range of 0.19% to 0.38% reflects the full distribution of porosity measurements across all sample points within all 14 rejected lots. It does not — and was never intended to — represent WAL's acceptance/rejection threshold.
67. Put simply: a lot with porosity measurements of 0.19% at one sample point and 0.32% at another sample point is properly rejected, because the 0.32% measurement exceeds the ≤0.25% contractual limit. The 0.19% measurement does not "save" the lot from rejection, nor does it indicate that WAL applied a threshold below 0.25%.
68. WAL will present detailed expert testimony from Dr. Raymond Chow of Arclight Materials Science Inc. demonstrating the sample-by-sample porosity measurements for each rejected lot and confirming that every lot rejection was based on measurements exceeding the contractual ≤0.25% threshold at one or more sample points.
C. WAL's Termination Under § 14.2(b) Was Proper
69. Kestrel alleges that WAL's termination of the MSA was pretextual and motivated by WAL's desire to replace Kestrel with a lower-cost domestic supplier, namely Valkyr Precision Components Inc. This allegation is central to Kestrel's theory of the case, and it is entirely unsupported by the evidence.
70. First, the allegation is refuted by the pricing evidence. Valkyr's unit price was €8,432.92 per unit — substantially higher, not lower, than Kestrel's CY4 price of €5,222.92 per unit. Even after accounting for Valkyr's introductory discount of 4.2%, Valkyr's adjusted unit price was approximately €8,078.74 per unit — a premium of approximately 54.7% over Kestrel's price. No rational commercial actor would terminate a functioning supply relationship and engage a replacement supplier at a 54.7% cost premium as a "cost-saving" measure. The economic reality of the situation is the opposite of what Kestrel alleges: WAL's engagement of Valkyr was a costly mitigation step forced upon WAL by Kestrel's quality failures.
71. Second, the allegation is refuted by the factual record. WAL did not begin soliciting alternative suppliers until after the pattern of quality failures had become evident and Kestrel had demonstrated an inability to cure. WAL's internal procurement records and communications demonstrate that the decision to engage Valkyr was made in response to Kestrel's Persistent Quality Failure, not as a premeditated strategy to terminate the MSA.
72. Third, the allegation is refuted by the contractual record. WAL documented seven uncured rejections within a single rolling 12-month period. The Persistent Quality Failure threshold under Section 8.4 is three. WAL exceeded the threshold by more than double. The objective, measurable criteria for a Persistent Quality Failure were unambiguously satisfied, and WAL was entitled to terminate under Section 14.2(b) as a matter of contractual right, regardless of its subjective motivations.
73. Finally, the termination notice itself was procedurally and substantively compliant with the MSA. The notice identified the specific contractual basis for termination (Section 14.2(b)), the underlying Persistent Quality Failure (seven uncured rejections exceeding the threshold of three), the specific lot numbers, and the applicable specifications. WAL's termination was an exercise of a validly invoked contractual remedy, not a breach.
D. The Consequential Damages Waiver (§ 8.7) Bars the Majority of Kestrel's Claims
74. Even if the Tribunal were to determine — contrary to the evidence and arguments presented herein — that WAL's termination of the MSA constituted a breach (which WAL vigorously denies), the consequential damages waiver in Section 8.7 of the MSA would bar the vast majority of Kestrel's claimed damages.
75. Section 8.7 establishes an exclusive remedy framework for quality-related disputes and expressly waives consequential damages. The waiver applies to both parties and encompasses all forms of consequential, incidental, special, punitive, and indirect damages, including lost profits, lost revenue, loss of use, and loss of business opportunities.
76. Of the four categories of damages claimed by Kestrel, three are unambiguously consequential in nature:
(a) Lost profits for the remaining MSA term (€12.83 million): Lost profits are the paradigmatic form of consequential damages. Kestrel's claim for profits it would have earned during the remaining term of the MSA had the contract not been terminated is a classic consequential damages claim barred by Section 8.7.
(b) Lost profits for the renewal periods (€27.15 million): This claim is even more attenuated than the remaining-term lost-profits claim, as it depends not only on the assumption that the MSA should not have been terminated but also on the speculative assumption that WAL would have exercised its discretionary renewal options. This claim is consequential and barred by Section 8.7.
(c) Reputational damages (€3.90 million): Claimed damages for harm to Kestrel's business reputation and loss of other business opportunities are inherently consequential in nature and are expressly encompassed within the scope of Section 8.7's waiver.
77. Under New York law, consequential damages waivers negotiated between sophisticated commercial parties in arm's-length transactions are routinely enforced. Courts in New York have consistently held that such waivers reflect the legitimate allocation of risk between contracting parties and should be given full effect absent fraud, duress, or unconscionability — none of which is alleged or demonstrated here. WAL's legal analysis of this point is set forth in greater detail in Section VIII.B below.
VI. RESPONSE TO KESTREL'S DAMAGES CLAIMS
78. In this Section, WAL addresses and rebuts each of the four categories of damages claimed by Kestrel in its Statement of Claim. WAL demonstrates that each category of damages is independently deficient for multiple reasons, including the propriety of WAL's termination, the applicability of the consequential damages waiver, and the failure of Kestrel's damages calculations to satisfy basic requirements of certainty, foreseeability, and causation under New York law.
A. Lost Profits — Remaining MSA Term (€12.83 million)
79. Kestrel claims €12.83 million in lost profits for the remaining term of the MSA (Contract Year 5, running from June 15, 2022 through June 14, 2023). Kestrel calculates this claim based on an assumed volume of 3,600 units at the CY5 unit price of €5,353.49, applied to a claimed profit margin of 22.4%.
80. This claim fails for multiple independent reasons:
(a) WAL's termination was proper. As demonstrated throughout this submission, WAL's termination of the MSA on October 3, 2022 was a lawful exercise of WAL's contractual right under Section 14.2(b), triggered by the occurrence of a Persistent Quality Failure. Kestrel has no entitlement to damages arising from a lawful termination. A party that exercises a valid contractual termination right is not liable for damages that the counterparty would have earned had the contract continued.
(b) Lost profits are consequential damages barred by Section 8.7. As discussed in Section V.D above, Kestrel's lost-profits claim is consequential in nature and falls squarely within the scope of the mutual consequential damages waiver negotiated by the parties in Section 8.7 of the MSA.
(c) Kestrel's claimed margin is inflated and unsupported. Kestrel asserts a profit margin of 22.4% without providing audited financial data or a transparent methodology for the calculation. WAL reserves its right to present expert evidence through Dr. Nadia Ostrovsky of Ridgeline Economic Consulting LLC demonstrating that Kestrel's actual margin on the MSA Products was materially lower than 22.4% when properly accounting for all direct and indirect costs, including raw material costs, labor, overhead, depreciation, logistics (including DDP costs), quality-assurance costs, rework costs, and other attributable expenses. WAL further reserves its right to present forensic accounting analysis by Canfield & Thorpe LLP (Sandra Gillespie, CPA/ABV) demonstrating the deficiencies in Kestrel's margin calculation.
(d) Kestrel uses an inflated volume assumption. Kestrel's calculation assumes a volume of 3,600 units for CY5. However, the MSA's minimum annual volume commitment is 2,400 units, not 3,600 units (Section 4.1). WAL had no obligation to order more than 2,400 units. To the extent lost-profits damages were recoverable at all (which WAL denies), the calculation should be based on the minimum contractual commitment, not on historical ordering patterns or the maximum volume. Kestrel's use of 3,600 units overstates the damages calculation by 50%.
B. Lost Profits — Renewal Periods (€27.15 million)
81. Kestrel claims €27.15 million in lost profits for the two optional one-year renewal periods following the expiration of the initial five-year term. This claim constitutes the single largest component of Kestrel's total damages, accounting for more than 57% of the €47.3 million claimed.
82. This claim is legally untenable and must be dismissed for the following reasons:
(a) The renewal options were exercisable solely at WAL's discretion. Section 3.1 of the MSA provides that the two one-year renewal periods are exercisable solely at WAL's option. The MSA does not impose any obligation on WAL to renew, does not create any reasonable expectation of renewal, and does not condition WAL's renewal decision on any particular criteria. WAL had complete, unfettered discretion to renew or not to renew the MSA at the conclusion of the initial term, and WAL could have declined to renew for any reason or no reason.
(b) Kestrel had no legally cognizable expectation interest in renewal-period profits. Under New York law, an option right held by one party does not confer a corresponding entitlement upon the counterparty. Kestrel's expectation that WAL might exercise its renewal options does not give rise to a legally protected interest. The renewal-period profits that Kestrel claims it would have earned are contingent upon a discretionary act by WAL — an act that WAL was under no obligation to take. Damages based on the non-occurrence of a discretionary event are inherently speculative and are not recoverable.
(c) The renewal-period damages are speculative. Even if damages for the renewal periods were theoretically available (which WAL denies), they would be impermissibly speculative. Kestrel's claim assumes that WAL would have exercised both renewal options, that Kestrel would have supplied Products at 3,600 units per year during the renewal periods, and that Kestrel would have maintained its claimed 22.4% margin throughout. Each of these assumptions is speculative, and the compounding of multiple speculative assumptions renders the resulting damages figure unreliable.
(d) The renewal-period lost-profits claim is consequential and barred by Section 8.7. For the same reasons set forth in connection with the remaining-term lost-profits claim, the renewal-period lost-profits claim is consequential in nature and is barred by the mutual consequential damages waiver in Section 8.7.
C. Unreimbursed Rework Costs (€3.42 million)
83. Kestrel claims €3.42 million for rework costs allegedly incurred by Kestrel in attempting to cure rejected lots by reworking or replacing non-conforming Products.
84. This claim is meritless for the following reasons:
(a) Rework was Kestrel's contractual cure obligation. Under Section 8.4 of the MSA, upon the rejection of a lot for non-conformance, Kestrel was obligated to cure the non-conformance by delivering replacement or reworked Products within the 45-calendar-day cure period. Rework and replacement were Kestrel's contractual obligations, not gratuitous services performed for WAL's benefit. Kestrel cannot recover costs incurred in performing — or attempting to perform — its own contractual obligations. The rework costs that Kestrel claims are costs that Kestrel was required to bear as part of its quality-assurance obligations under the MSA.
(b) Cured lots were accepted. To the extent Kestrel incurred rework costs on lots that were ultimately successfully cured and accepted by WAL, those costs were a normal cost of performance under the MSA. Kestrel received payment for the cured lots at the contractual unit price, and the rework costs were part of Kestrel's cost of goods sold. There is no contractual or legal basis for shifting these costs to WAL.
(c) Failed cures are not WAL's responsibility. For lots that remained uncured despite Kestrel's rework efforts, the failure to cure is attributable to Kestrel, not to WAL. Kestrel's inability to bring non-conforming Products into compliance with the contractual specifications — even after being given the extended 45-day cure period — does not give rise to a claim against WAL for the costs of Kestrel's failed cure efforts. To hold otherwise would create a perverse incentive: a seller could deliver non-conforming goods, incur rework costs in an unsuccessful attempt to cure, and then recover those costs from the buyer.
(d) The rework costs are, in any event, barred by Section 8.7. Section 8.7 establishes replacement, credit, and termination as the exclusive remedies for quality failures. There is no contractual basis for Kestrel to recover rework costs from WAL, and to the extent such costs are characterized as damages, they are consequential in nature and barred by the Section 8.7 waiver.
D. Reputational Damages (€3.90 million)
85. Kestrel claims €3.90 million for alleged reputational harm and loss of other business opportunities resulting from WAL's termination of the MSA.
86. This claim is deficient for multiple independent reasons:
(a) Reputational damages are consequential and barred by Section 8.7. Damages for reputational harm and loss of business opportunities are inherently consequential in nature. They represent indirect, downstream consequences of the alleged breach — specifically, the alleged impact of WAL's termination on Kestrel's relationships with other customers and its ability to secure other contracts. Such damages fall squarely within the scope of the consequential damages waiver in Section 8.7.
(b) The claim is speculative, remote, and unsupported. Under New York law, damages for reputational harm are recoverable only upon proof of specific, quantifiable lost opportunities that are directly and foreseeably caused by the alleged breach. Kestrel has not identified any specific customer that it lost, any specific contract that it failed to secure, or any specific revenue that it forfeited as a result of WAL's termination of the MSA. Kestrel's claim is based on generalized assertions of harm to its "market reputation" and "competitive standing" without any supporting evidence of concrete, identifiable losses.
(c) Causation is not established. Even if Kestrel could identify specific lost business opportunities, it would need to establish that those losses were caused by WAL's termination of the MSA, rather than by other factors such as Kestrel's own quality failures, competitive dynamics in the aerospace supply market, or general market conditions. The termination itself was prompted by Kestrel's quality failures; to the extent Kestrel's reputation suffered, the more proximate cause was Kestrel's inability to deliver conforming products, not WAL's contractually justified termination.
E. Summary of Damages Defense
87. For the reasons set forth above, all four categories of Kestrel's claimed damages — totaling approximately €47.3 million — should be dismissed in their entirety. The following table summarizes WAL's defenses to each category of damages:
VII. RESPONDENT'S COUNTERCLAIM
A. Basis for the Counterclaim
88. In addition to defending against Kestrel's unfounded claims, WAL asserts a counterclaim against Kestrel in the amount of €5.17 million, representing the cost premium incurred by WAL in procuring replacement Ti-6Al-4V ELI titanium alloy turbine housings from Valkyr Precision Components Inc. following Kestrel's Persistent Quality Failure. This counterclaim is asserted pursuant to the ICC Rules of Arbitration and Section 22.3 of the MSA, and WAL requests that the Tribunal adjudicate the counterclaim in conjunction with Kestrel's claims.
B. Factual Basis
89. As set forth in Section IV.F above, Kestrel's repeated failure to deliver specification-compliant Products — culminating in a Persistent Quality Failure comprising seven uncured lot rejections — left WAL with an urgent need to procure 1,680 replacement units from an alternative supplier. WAL engaged Valkyr Precision Components Inc., an AS9100 Rev D-certified manufacturer of aerospace-grade titanium alloy components, as its replacement supplier after conducting a competitive solicitation among qualified alternatives.
90. The relevant pricing data for the counterclaim calculation is as follows:
(a) Valkyr's unit price: €8,432.92
(b) Kestrel's CY4 unit price (the applicable contract price at the time of the quality failures): €5,222.92
(c) Per-unit cost premium: €8,432.92 − €5,222.92 = €3,210.00